Xenon Pharmaceuticals is a clinical stage biopharmaceutical company focused on developing therapeutics for patients with neurological disorders. Co.'s product candidates include: XEN1101, a Kv7 potassium channel modulator being developed for the treatment of epilepsy and potentially other neurological disorders; XEN496, a Kv7 potassium channel modulator for the treatment of KCNQ2 developmental and epileptic encephalopathy; and XEN007, a CNS-acting calcium channel modulator that modulates Cav2.1 and T-type calcium channels. Co. has a license and collaboration agreement with Neurocrine Biosciences, Inc. to develop treatments for epilepsy. The XENE stock yearly return is shown above.
The yearly return on the XENE stock yearly return page and across the coverage universe of our site,
is a measure of the annual return over the calendar year 2018 for the given stock.
When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is
more than just the change in price if that instrument pays a dividend or coupon.
One way to factor dividends into the return is simply to count them as cash — we don't do
that here. Instead, our website aims to empower investors
by performing the XENE annual return calculation with any dividends reinvested as applicable (on ex-dates).
|